ReviewNature reviews. Clinical oncology2019
Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned.
Review in Nature reviews. Clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it, 66 citations in OpenAlex.
- Active Surveillance Versus Thyroid Surgery for Differentiated Thyroid Cancer: A Systematic Review.Thyroid : official journal of the American Thyroid Association · 2022Pooled it
- A comparative study of large language models (ChatGPT/DeepSeek) in generating structured thyroid ultrasound reports.Scientific reports · 2026Article
- Predictive Biomarkers for Asymptomatic Adults: Opportunities, Risks, and Guidance for General Practice.Diagnostics (Basel, Switzerland) · 2026Review
- Assessing agreement with a single-center expert consensus: artificial intelligence-assisted teleultrasound for thyroid nodules categorized as C-TIRADS 4A or higher.Frontiers in endocrinology · 2026Article
- Performance of GPT-4 for automated prostate biopsy decision-making based on mpMRI: a multi-center evidence study.Military Medical Research · 2025Article
- Personalized Biopsy Schedules Using an Interval-Censored Cause-Specific Joint Model.Statistics in medicine · 2025Article
- Unveiling the mysteries of extrachromosomal circular DNA: from generation to clinical relevance in human cancers and health.Molecular cancer · 2024Review
- Validation of a prognostic blood-based sphingolipid panel for men with localized prostate cancer followed on active surveillance.Biomarker research · 2024Article
- Article
- Hormones as a double-edged sword: the role of hormones in cancer progression and the potential of targeted hormone therapies.Medical oncology (Northwood, London, England) · 2024Review
- Leveraging cell death patterns to predict metastasis in prostate adenocarcinoma and targeting PTGDS for tumor suppression.Scientific reports · 2024Article
- DNA ploidy and PTEN as biomarkers for predicting aggressive disease in prostate cancer patients under active surveillance.British journal of cancer · 2024Article
- Decision regret after prostate biopsy for prostate cancer diagnosis: a Korean multicenter cohort study.BMC public health · 2024Article
- Elucidating immune-related gene transcriptional programs via factorization of large-scale RNA-profiles.iScience · 2024Article
- Racial and Ethnic Variation in Receipt and Intensity of Active Surveillance for Older Patients With Localized Prostate Cancer.Urology practice · 2024Article
- Underlying effect of SMAD4 gene polymorphism on risk prediction of papillary thyroid carcinoma in Chinese population.Heliyon · 2024Article
- Article
- Retrospective study of BRAFPeerJ · 2024Article
- Trends of the prevalence rate of central lymph node metastasis and multifocality in patients with low-risk papillary thyroid carcinoma after delayed thyroid surgery.Frontiers in endocrinology · 2024Article
- High expression of IL4I1 is correlated with poor prognosis and immune infiltration in thyroid cancer.BMC endocrine disorders · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
The adverse effects of overdiagnosis and overtreatment observed in men with clinically insignificant prostate cancers after the introduction of prostate-specific antigen-based screening are now being observed in those with thyroid cancer, owing to the introduction of new imaging technologies. Thus, the evolving paradigm of active surveillance in prostate and thyroid cancers might be valuable in informing the development of future active surveillance protocols. The lessons learned from active surveillance and their implications include the need to minimize the use of broad, population-based screening programmes that do not incorporate patient education and the need for individualized or shared decision-making, which can decrease the extent of overtreatment. Furthermore, from the experience in patients with prostate cancer, we have learned that consensus is required regarding the optimal selection of patients for active surveillance, using more-specific evidence-based methods for stratifying patients by risk. In this Review, we describe the epidemiology, pathology and screening guidelines for the management of patients with prostate and thyroid cancers; the evidence of overdiagnosis and overtreatment; and provide overviews of existing international active surveillance protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.